1 |
Njue C. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products. Biologicals, 2011;39(5):266-269.
|
2 |
식품의약품안전청, 식품의약품안전평가원. 동등 생물의약품 평가 가이드라인. Seoul (Korea) 2009.
|
3 |
World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2012.
|
4 |
Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product (Draft). 2012.
|
5 |
European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies (EMA/CHMP/BMWP/ 403543/2010). http://wwwemaeuropaeu/docs/en_GB/ document_library/Scientific_guideline/2010/11/W C500099361pdf. 10/2010, 2010. [Online] (last visited on Feb 13 2012).
|
6 |
Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Non-inferiority clinical trials (Draft). March 2010.
|
7 |
Greene CJ, Morland LA, Durkalski VL, Frueh BC. Noninferiority and equivalence designs: issues and implications for mental health research. J Traum Stress, 2008;21(5):433-439.
|
8 |
Hwang IK, Morikawa T. Design Issues in Noninferiority/Equivalence Trials. Drug Inf J, 1999;33(4):1205-1218.
|
9 |
United States Government Accountability Office. New drug approval: FDA's consideration of evidence from certain clinical trials. Washington, DC, USA: United States Government Accountability Office. 2010.
|
10 |
Committee for Medicinal Products for Human Use (CHMP). Guideline on the Choice of the Non-inferiority margin. EMEA/CPMP/EWP/2158/99. London (UK) July 27, 2005.
|
11 |
Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects metaanalysis. J R Stat Soc Ser A, 2009;172(1): 137-159.
|
12 |
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986;7(3): 177-188.
|
13 |
The Cochrane Collaboration. 9.5.4 Incorporating heterogeneity into random-effects models. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011] 2011.
|
14 |
McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther, 2012;91(3):405-417.
|
15 |
Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol, 2008;19(3): 411-419.
|